NeuroMetrix Q2 2023 Earnings Report $3.90 0.00 (0.00%) (As of 12/20/2024 05:31 PM ET) Earnings History NeuroMetrix EPS ResultsActual EPS-$1.52Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ANeuroMetrix Revenue ResultsActual Revenue$1.66 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ANeuroMetrix Announcement DetailsQuarterQ2 2023Date7/27/2023TimeN/AConference Call ResourcesNURO Earnings History Could This Tiny Device Help You Make an Extra $30k a Year? (Ad)I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more than $9 trillion. That’s nearly 10 times more money than the market caps of Tesla… SpaceX… PayPal… Neuralink… and X… COMBINED.Click here to see the details because I believe a lot of people will get rich. NeuroMetrix Earnings Headlines$TOCKHOLDER ALERT: The M&A Class Action Firm Is Investigating the Merger – PWOD, CARA, NURO, VOXXDecember 20 at 2:59 AM | markets.businessinsider.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NURO, CARA, ZUO, BMTX on Behalf of ShareholdersDecember 18, 2024 | stockhouse.comWhy Buffett, Griffin and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this window of opportunity is closing fast.December 22, 2024 | Behind the Markets (Ad)SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating NeuroMetrix, Inc. BuyoutDecember 18, 2024 | markets.businessinsider.comSHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of NeuroMetrix, Inc. - NURODecember 18, 2024 | prnewswire.comElectroCore to Buy NeuroMetrix, Adding Quell PlatformDecember 18, 2024 | marketwatch.comSee More NeuroMetrix Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like NeuroMetrix? Sign up for Earnings360's daily newsletter to receive timely earnings updates on NeuroMetrix and other key companies, straight to your email. Email Address About NeuroMetrixNeuroMetrix (NASDAQ:NURO), a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.View NeuroMetrix ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Upcoming Earnings Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
